A positron emission tomography imaging study to confirm target engagement in the lungs of patients with idiopathic pulmonary fibrosis following a single dose of a novel inhaled αvβ6 integrin inhibitor

Table 4 Summary of Derived Plasma GSK3008348 Pharmacokinetic Parameters

PK Parameter (units)	N	Period	Geometric Mean	95% CI	%CVb
AUC(0-t) *(hpg/mL)**	5	Period 1	64,638	(33,065, 126,362)	58
AUC(0-t) *(hpg/mL)**	5	Period 2	66,123	(39,036, 112,005)	44
C_max (pg/mL)	5	Period 1	14,050	(8876, 22,243)	38
C_max (pg/mL)	5	Period 2	10,418	(7191, 15,094)	31
T_max¹ (h)	5	Period 1	0.50	(0.4–0.5)
T_max¹ (h)	5	Period 2	0.47	(0.4–0.5)

AUC_0–t area under the concentration-time curve from time zero to time of last quantifiable concentration; C_max maximum plasma concentration; T_max time to maximum plasma concentration
¹T_max expressed as median (range)

ISSN: 1465-993X